

Amendments to the Title:

Please change the title of the invention to the following:

---A Vaccine for Induction of Adaptive Immune Response Against Tumor Antigens---

Amendments to the Specification:

At page 1 of the Specification, before the "FIELD OF THE INVENTION" header and following the title, please insert the following header and paragraph:

CROSS-REFERENCES TO RELATED APPLICATIONS

[0000] This application claims the benefit of U. S. Provisional Application Serial No. 60/425,286 entitled "E7/CD40 Ligand Vector for Induction, Activation, Antigen Loading and Mobilization of Antigen Presenting Cells", filed November 12, 2002, and PCT Application PCT/US2003/036237, entitled "Adenoviral Vector Vaccine", each of which is incorporated by reference herein in its entirety.

Please replace paragraph 0106 on page 29 with the following amended paragraph.

[0106] To quantify the expression level of surface molecules of APCs or DCs, the test cells were stained with FITC- or PE-conjugated anti-mouse monoclonal antibodies (mAbs) for CD80, CD54, and CD11c (PharMingen), for 30 min on ice, prior to immunostaining with labeled Abs. The APCs were first incubated with a Fc- γ blocking antibody (anti-mouse CD16/CD32 antibody) to avoid the nonspecific binding of mAbs to Fc- γ receptors. The cells were then washed twice, fixed in 4% paraformaldehyde, and analyzed using a Becton Dickinson flow cytometer (BD FACSCalibur™).

Please replace paragraph 0121 on page 32 with the following amended paragraph.

[0121] All parameters were analyzed using Students t test, or ANOVA® followed by Scheffé's procedure for multiple comparisons as post-hoc analysis; all data shown is presented as mean \pm S.E. of the mean (S.E.).